液体复苏在高呼吸末正压通气导致的肺泡微循环障碍中的作用

目的明确高呼气末正压（PEEP）条件下肺泡微循环的变化情况以及液体复苏在高PEEP情况下对肺泡微循环的影响。 方法选用北京当地的15条健康成年杂种狗进行实验，分别观察基线（PEEP 5 cmH₂O，1 cmH₂O=0.098 kPa）、高PEEP（平均动脉压下降≥20 mmHg，1 mmHg=0.133 kPa）及液体复苏后的呼吸、系统循环及肺泡微循环情况，肺泡微循环利用旁流暗视野成像（SDF）技术进行观察、留取视频结果，线下利用AVA3.2软件进行分析，不同条件下的实验数据之间的差异利用Wilcoxon秩和检验进行分析。 结果高PEEP可导致中心静脉压（CVP）升高（P=0.001）及心输出量（CO）下降（P=0.002），肺泡微循环表现为总微血管数量（TVDa，P=0.036）、灌注血管数量（PVDa，P=0.002）、灌注血管比例（PPVa，P=0.003）、血流状态（MFIa，P=0.002）显著下降，肺泡周围毛细血管密度下降不明显（TVDs，P=0.319）；液体复苏恢复整体循环后，微循环参数均无显著改善。 结论过高的PEEP水平可导致肺泡微循环的显著恶化，通过液体复苏不能改善由此产生的微循环障碍。     

局部晚期食管鳞癌新辅助放疗剂量与病理完全缓解关系分析

目的 探讨接受新辅助放化疗的局部晚期食管鳞癌患者新辅助放疗剂量与病理完全缓解(pCR)的关系。方法 收集2017-2019年间在四川大学华西医院肿瘤中心经病理确诊为食管鳞癌并接受新辅助放化疗和手术的 116例局部晚期患者临床资料。116例患者中 40~45Gy组 80例,≥45Gy组 36例,分析两组术后pCR率。结果 全组患者的pCR率为38.8%(45/116),40~45Gy组与≥45Gy组的pCR率分别为44%(35/80)和28%(10/36)(P=0.105)。结论 术前新辅助采用较高的放疗剂量不增加局部晚期食管鳞癌的pCR率,有必要进行前瞻性的临床研究确定合适的新辅助放疗剂量。     

Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup

Diffuse large B-cell lymphoma (DLBCL) is a clinically aggressive and heterogenous disease. Although most patients can be cured by immunochemotherapy, 30% to 40% patient will ultimately develop relapsed or refractory disease. Here, we investigated the molecular landscapes of patients with diverse responses to R-CHOP. We performed capture-based targeted sequencing on baseline samples of 105 DLBCL patients using a panel consisting of 112 lymphoma-related genes. Subsequently, 81 treatment-naïve patients with measurable disease and followed for over 1 year were included for survival analysis. Collectively, the most commonly seen mutations included IGH fusion (69%), PIM1(33%), MYD88 (29%), BCL2 (29%), TP53 (29%), CD79B (25%) and KMT2D (24%). Patients with TP53 mutations were more likely to have primary refractory disease (87.0% vs 50.0%, P = .009). For those with TP53 disruptive mutations, 91.7% patients were in the primary refractory group. Interestingly, BCL-2 somatic hypermutation was only seen in patients without primary refractory disease (P = .014). In multivariate analysis, BCL-2 amplification (hazard ratio [HR] = 2.94, P = .022), B2M mutation (HR = 2.99, P = .017) and TP53 mutation (HR = 3.19, P < .001) were independently associated with shorter time to progression (TTP). Furthermore, TP53 mutations was correlated with worse overall survival (P = .049). Next, we investigated mutation landscape in patients with wild-type (WT) TP53 (n = 58) and found that patients harboring MYD88 L265P had significantly inferior TTP than those with WT or non-265P (P = .046). Our study reveals the mutation spectrum of treatment-naive Chinese DLBCL patients. It also confirms the clinical significance of TP53 mutations and indicates the prognostic value of MYD88 L265P in TP53 WT patients.